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Abstract  
Current criteria for the diagnosis of chronic kidney disease (CKD) in adults include persistent 
signs of kidney damage; for example, increased urine albumin-to-creatinine ratio or a 
glomerular filtration rate (GFR) below the threshold of 60 mL/min per 1.73m2. The latter has 
important caveats. This threshold does not separate kidney disease from kidney aging, and 
therefore does not hold for all ages. In an extensive review of the literature, we found that 
GFR declines with healthy aging without any overt signs of compensation (such as elevated 
single nephron GFR) or kidney damage. Older living kidney donors, who are carefully 
selected based on good health, have a lower pre-donation GFR compared to younger donors. 
Furthermore, the results of the large meta-analyses conducted by the CKD Prognosis 
Consortium and of numerous other studies indicate that the GFR threshold above which the 
risk of mortality is increased, is not consistent across all ages. Among younger persons, 
mortality is increased at GFR lower than 75 mL/min per 1.73m2, whereas in elderly people it 
is increased at levels lower than 45 mL/min per 1.73m2. Therefore, we suggest the CKD 
definition to be amended to include age-specific thresholds for GFR. The implications of an 
updated definition are far reaching. Fewer elderly would be diagnosed with CKD, reducing 
inappropriate care and its associated adverse effects. Prevalence estimates for CKD globally 
would be substantially reduced. Furthermore, the onset of CKD may be identified sooner in 
younger persons, and at a point when progressive kidney damage may still be preventable.  
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Introduction  
Perspectives on the definition of CKD 
The current criteria used for the definition of chronic kidney disease (CKD) in adults are: 1) 
signs of kidney damage, most often determined by an elevated urine albumin (or protein)-to-
creatinine ratio (ACR) or 2) glomerular filtration rate (GFR) less than 60 mL/min per 1.73m², 
as GFR is considered the best determinant of kidney function 1. CKD is staged according to 
six GFR categories (G1, G2, G3a, G3b, G4 and G5) and three categories for urine ACR levels 
(A1, A2 and A3) (Table 1). There is a broad agreement that abnormal urine ACR should 
trigger a diagnosis of CKD, but controversy remains regarding the most appropriate 
diagnostic criteria regarding GFR. In this article, we will focus on the role of GFR in the 
definition of CKD. Laboratory thresholds for disease identification are commonly determined 
in two ways 2–4. First, the distribution of the laboratory results in a representative population 
of healthy persons is obtained and thresholds for defining disease are calculated according to 
extreme values based on this distribution (typically 95th or 97.5th percentile for “too high” and 
2.5th or 5th percentile for “too low”). Second, a threshold associated with an adverse outcome 
is identified through epidemiologic studies. These two strategies (reference distribution and 
prognosis) will be considered and discussed in the specific case of using GFR for CKD 
definition.     
 
The current CKD definition and its caveats 
The current and widely adopted definition of CKD in adults is based on the 2013 KDIGO 
guidelines 1. Although not entirely undisputed, we do recognize the merit of these guidelines 
as they standardized the definition of CKD 5–11. As pointed out, GFR is one of the two main 
criteria for diagnosis of CKD. More importantly, an isolated GFR below 60 mL/min per 
1.73m² (confirmed with a second value after at least 90 days) suffices for the diagnosis of 
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CKD. In other words, anyone with a GFR below 60 mL/min per 1.73m² persisting for at least 
three months by definition has CKD, even if the urine ACR and structure or kidney 
morphology (imaging or biopsy) are normal (e.g. G3a/A1). This threshold of 60 mL/min per 
1.73m² is irrespective of age. The considerations in favor of a fixed threshold at 60 mL/min 
per 1.73m² in the current CKD definition proposed by KDIGO are as follows 1:  
a) simplicity: only one number needs to be kept in mind. This argument is understandably 
relevant for non-nephrologists and patients, but carries the risk of oversimplification of 
the complexities of kidney pathophysiology.  
b) biology: 60 mL/min per 1.73m² is believed to represent less than 50% of the kidney 
function measured in healthy, young adults 1. The choice of 50% of normal function is 
however quite arbitrary.  Moreover, whether GFR is actually ≈120 mL/min per 1.73m² 
in healthy young adults is debatable. This value was originally based on measured GFR 
(mGFR) values compiled and published in 1969 by Wesson 12. More recent studies 
have shown that median GFR values in healthy young adults are lower than 120 
mL/min per 1.73m² 13–15. Indeed, one meta-analysis of mGFR data in living kidney 
donors (n=5,482), showed normal mean GFR values of 106.7 mL/min per 1.73m² at 
age 20-30 years 14. Such values were also observed in a large cohort of 2,007 French 
living kidney donors below 40 years of age, with a mean mGFR of 107.2 mL/min per 
1.73m² 15.  
c) prognosis: the last argument for a threshold at 60 mL/min per 1.73m² was based on the 
association of lower GFR values with morbidity and mortality. The choice for the 
threshold at 60 mL/min per 1.73m² has seemingly been supported by many large 
epidemiological studies, especially from the CKD Prognosis Consortium. We will 
discuss this argument in depth below.  
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The prognostic argument for an age-adapted definition of CKD 
Absolute risks of mortality are typically higher in older patients due to the limited human 
lifespan. Regarding relative risk, several studies from the CKD Prognosis Consortium have 
demonstrated that GFR lower than 60 mL/min per 1.73m² was independently associated with 
adverse outcomes, in particular cardiovascular events and all-cause mortality 16–28, thereby 
confirming the seminal study published by Go et al. in 2004 29. Of note, most of the 
Consortium analyses of GFR and risk of adverse events in both high-risk and general 
populations use as the reference group participants with only a single estimated GFR (eGFR) 
available (hence, no confirmation of chronicity) ≥ 95 mL/min per 1.73m² 16–28. However, in 
their meta-analysis that included more than 2 million subjects from 46 different cohorts (33 
cohorts from the general population and 13 CKD cohorts) that was dedicated to the effect of 
age, the reference group eGFR used was 80 mL/min per 1.73m² rather than 95 mL/min per 
1.73m² 17. The associations with mortality and end-stage renal disease (ESRD) remained 
significant when eGFR was lower than 60 mL/min per 1.73m² in all age categories, although 
hazard ratios (HR) were much lower in older people 17. While the risk of ESRD was 
increased, the progression to ESRD in elderly patients with an eGFR of 45 to 59 mL/min per 
1.73m² and no abnormal urine ACR is very rare (<1% risk in 5 years using the Kidney Failure 
Risk Equation)30. The choice of the reference group is of critical importance in such analyses 
and the data from the CKD Prognosis Consortium for mortality have therefore been re-
analyzed by others using different reference groups based on age (Figure 1) 31–34. In these 
analyses 31,34, the reference eGFR group in each age-category was defined as the one with the 
lowest mortality risk (in subsets with urine ACR <10 or 10-29 mg/g). The results revealed 
that in the 55 to 64 year age category (reference eGFR 90-104 mL/min per 1.73m²), the 
mortality risk began to increase when GFR fell below 60 mL/min per 1.73m². However, for 
subjects older than 65 years (reference eGFR 75-89 mL/min per 1.73m²), the risk was trivial 
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until the eGFR had fallen below 45 mL/min per 1.73m². In the youngest age category 18-54 
years (reference eGFR above 105 mL/min per 1.73m²), the risk of mortality started to increase 
when eGFR was below 75 mL/min per 1.73m² 31–34. Therefore, an age-specific analysis of the 
data used by the CKD Prognosis Consortium provides a strong argument for an age-adapted 
definition of CKD using prognostic strata appropriate for age.  
Tables 2 and 3 summarize the studies on associations between eGFR and risk of adverse 
events outside of the CKD Prognosis Consortium. Only published full-length articles were 
considered in this analysis. Included are studies that used creatinine-based equations 
(Modification of Diet in Renal Disease equation (MDRD) Study or Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equations) and reported adjusted risks of 
cardiovascular or all-cause mortality 29,35–55. We excluded studies that included only subjects 
with eGFR categories G3-G5 and those that excluded older subjects. Instead we focused on 
studies that were performed in elderly individuals or reported results in separate age 
categories. Our main hypothesis was that the increased risk of mortality associated with low 
eGFR differs across age categories and, notably, that in older age groups eGFR between 45 
and 60 mL/min per 1.73m² is not associated with excess mortality. When looking at studies 
that presented a separate eGFR category between 45 and 60 mL/min per 1.73m² and used 
eGFR > 60 mL/min per 1.73m² as a reference category, only a few studies demonstrated an 
increased risk 43,45,49,56, whereas others reported no increase in risk 40,41,47,48. The largest study 
to date included a separate analysis of individuals with eGFR between 50 and 60 mL/min per 
1.73m² in the older age categories. The results showed that in this eGFR category the risk of 
death was not higher than in the category eGFR above 60 mL/min per 1.73m² 36. In addition, 
the Renal Risk in Derby study deserves particular attention as it included follow-up data on 
eGFR 55. A total of 1,741 subjects, most with confirmed CKD were prospectively followed 
for 5 years. The mean age of the cohort was 72.9±9 years, the mean eGFR using the CKD-
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EPI equation was 54±12 mL/min per 1.73m² and most participants had normal urine ACR. 
After 5 years, 34.1% of the cohort was considered as being stable and 19.3% had even 
improved their GFR category. Nearly all the subjects who improved their CKD status had 
been classified as category G3a/A1 at baseline 55. Interestingly, the age- and sex-standardized 
mortality rates of those with category G3a were similar to those in the general population, 
while those with category G3b or G4 at baseline had higher mortality rates 55,57.  
Regarding the prognosis argument, we acknowledge that our proposal of an age-adapted 
definition for CKD is mainly based on mortality risk. We did not consider other outcomes, 
even though other publications have reported the risk of lower GFR with classic metabolic 
complications of CKD (anemia, hyperparathyroidism, acidosis, hyperphosphoremia) 58,59 and 
other clinical complications (frailty, impaired quality of life, fracture etc.) 60,61. These studies 
unfortunately are of little utility in informing our proposal current of age-adapted threshold. 
While, if higher risk of these complications, is frequently observed when eGFR is below 45 
mL/min per 1.73m² 58, results are very variable for higher eGFR, notably because the 
definitions of the complication or of the clinical status are not uniform (contrary to the death 
status). 
In conclusion, most studies showed no or trivial additional mortality risk for older adult 
subjects with eGFR between 45 and 60 mL/min per 1.73m² and normal urine ACR. 
Prognostic arguments thus favor an age-adapted threshold for eGFR in the CKD definition.   
 
Kidney senescence as an argument for an age-adapted definition of CKD 
Structural differences between aging kidney and CKD 
Another concern with an GFR threshold fixed at 60 mL/min per 1.73m² is that it fails to 
account for the distinct micro- and macro-structural differences between the aging kidney and 
kidneys affected by CKD. In healthy kidney donors, aging is reflected by a slow indolent 
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nephrosclerosis, characterized by arteriosclerosis, ischemic globally (but not segmentally) 
sclerotic glomeruli, and interstitial fibrosis and tubular atrophy (IFTA)62. Despite the IFTA 
with aging being fairly minimal 62, there is a substantial nephron loss and dropout (from about 
1,000,000 nephrons per kidney in healthy 18-29 year olds to 500,000 per kidney in healthy 
70-75 year olds) 63. Despite this substantial nephron loss with age, there is no compensation 
by the remaining nephrons as glomerular volume, single-nephron GFR, and single-nephron 
glomerular filtration capacity remains stable 63–65. CKD on the other hand is often 
characterized by disease-specific pathology that differs from age-induced nephrosclerosis. 
CKD can include unique micro-structural findings (e.g., specific immunofluorescent staining 
patterns) or macro-structural findings (e.g. polycystic kidney or renal artery stenosis) that are 
not seen with aging alone. Although risk factors for CKD, including obesity, diabetes and  
hypertension, are associated with nephrosclerosis, they are also associated with glomerular 
enlargement, segmental glomerulosclerosis and higher single-nephron GFR in intact non-
sclerotic glomeruli 63,64. Only when the degree of global glomerulosclerosis exceeds that 
expected for age or when there is increased metabolic demand (e.g., obesity and 
hyperglycemia) is there an increase in single-nephron GFR. Therefore, application of age-
adapted thresholds for glomerulosclerosis is also useful with kidney biopsies performed in 
clinical care, as only glomerulosclerosis exceeding that expected for age is a risk factor for 
CKD progression 66,67.  
Decline of GFR with aging 
As already stated, the definition of normality for laboratory results can also be obtained by the 
distribution of the results in healthy populations. Establishing reference interval values with a 
fixed threshold as per the KDIGO guidelines would mean that the GFR reference values are 
constant across all age categories 13,14,68–81. However, more reliable studies using mGFR and 
realized in living kidney donors or healthy subjects selected from the general population 
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indicate a clear decrease in GFR with age 13–15,64,68–90, and the rate of mGFR decline becomes 
significant after the age of 40 years 2,12–15,73,76,80,85,88,91,92. Importantly, such a decline in mGFR 
with aging has been established on different continents and in different ethnic groups 68,77,79–
81,87,89. From these data, it is obvious that a substantial proportion of healthy older people have 
a mGFR below 60 mL/min per 1.73m² despite the paucity of studies that have focused on the 
elderly and used mGFR. Regarding eGFR 93–95, available cross sectional studies from 
different parts of the world confirmed that many people older than 65 years of age have an 
eGFR value lower than 60 mL/min per 1.73m², suggesting a rather ubiquitous decline of 
eGFR with age 13,68,96–101. Unfortunately, the few published longitudinal studies have shown 
discrepancies in the rate of kidney function decline or suffered from methodological 
limitations, such as use of eGFR or 24-h-creatinine clearance, inclusion of non-healthy 
subjects, limited follow-up duration, and study attrition, making it difficult to draw a 
definitive conclusion about the magnitude of the average rate of GFR decline with aging. 
Despite these limitations, all studies have shown a significant decline in GFR with aging in 
the majority of healthy subjects 48,96,102–114. The only longitudinal study using mGFR in a 
healthy general population is the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6), 
which included a representative sample of 1,594 Caucasians aged 50 to 62 years from the 
general population without CKD, diabetes, or cardiovascular disease. Iohexol clearance 
measurement was repeated in 1,299 (81%) patients after a median time of 5.6 years. The 
authors showed a mean GFR decline rate of 0.84±2.00 mL/min per year (or 0.95±2.23 
mL/min per 1.73m² per year). Although this may be the most valid study to date, it 
nevertheless had some limitations: it included only middle-aged Caucasians and had a 
relatively short follow-up with only two measurements in the majority of subjects 114. 
 
Proposals for an age-adapted CKD definition 
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The concept of an age-adapted definition of CKD is not new and has been proposed by 
different authors 2,3,8,10,31,33,34,36,64,98,99,115–124. Such age-adaptation could be achieved in 
different ways. We emphasize that the suggested change in CKD definition only pertains to 
people without other evidence of kidney damage (notably with normal urine ACR).   
Age-related percentiles of GFR 
First, one can use percentiles of GFR in the healthy population, which are available in the 
literature for mGFR and/or eGFR in different ethnic groups 13,68,96–99. In practice, this would 
mean that a GFR result is interpreted in the light of age-specific GFR percentiles, and that 
CKD would be defined as a value below a given percentile in healthy persons (Figure 2). By 
relating measurements to percentiles using different mGFR or eGFR methods, this approach 
may overcome differences in mGFR measurement techniques 125,126 or eGFR equations 
93,94,127. Using percentiles for each year of age minimizes the “birthday paradox” (where 
healthy people can become diseased or diseased people can “recover”, simply by becoming 
one year older), which is inherent to a single threshold approach or an age-based approach 
with only a few thresholds. By employing age-specific means and standard deviations, the 
individual patient levels can be transformed into a standard deviation score (SDS), a metric 
commonly used in pediatrics or even in adults for diagnosing other diseases like osteoporosis 
with bone mass density. An SDS value of minus 2 or less corresponds to an mGFR/eGFR at 
the 2.5th percentile or lower. Calculation of an SDS score requires well-
characterized reference values across the whole age spectrum. Using these data, GFR-SDS 
can be reported directly by the laboratory analogous to the eGFR results. The SDS is age- and 
method-independent and therefore ideal for follow-up. Furthermore, reference values may be 
included in the laboratory report (Figure 2). 
A limited set of age-specific thresholds 
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One can consider the CKD staging based on three different pivotal ages (Figure 3): <40 years, 
40-65 years, and >65 years. For the youngest cohort, we suggest a cut-off of 75 mL/min per 
1.73m², for individuals aged between 40 and 65 years, we suggest a GFR cut-off of 60 
mL/min per 1.73m² and 45 mL/min per 1.73m² for those older than 65 years. In other words, 
in subjects aged above 65 years, the current CKD category G3a/A1 (GFR 45 to 60 mL/min 
per 1.73m²) would not be considered a disease. Moreover, if the GFR is below 75 mL/min per 
1.73m² in young people, they would be considered to have CKD, as their kidney function is 
below what would be expected for their age. 31,34,97,120,123,128,129. The choice of the different 
GFR thresholds can be justified by associations of these thresholds with prognosis (Figure 1).  
 
The potential impact of an updated definition of CKD  
A modification of the CKD definition would have a substantial impact on the estimation of 
CKD prevalence. The KDIGO guidelines used the data from the NHANES study (1999-2006) 
and estimated the CKD prevalence in the US adult general population at 11.5%. Subjects with 
GFR between 45 and 60 mL/min per 1.73m² and normal urine ACR represented 3.6% of the 
general population and 75% of all patients with CKD were classified as such solely by the 
GFR criterion. Subjects with category G3a/A1 represented more than 30% of all people with 
CKD 1. Categories 3 or 3a are unequivocally the largest or second largest group in terms of 
CKD prevalence in other studies as well 47,48,55,56,97,123,130–139. The epidemiological literature 
clearly shows that CKD prevalence increases with age when using the fixed-threshold CKD 
definition of 60 mL/min per 1.73m²  1,48,56,97,101,123,130–134,138–143. Most older “patients” have a 
GFR of 45 to 60 mL/min per 1.73m², and normal urine ACR, whereas the younger patients 
more frequently have elevated urine ACR and GFR over 60 mL/min per 1.73m² 53,97,134,144. 
Thus, among the 3.6% of the general population with normal urine ACR and GFR between 45 
and 60 mL/min per 1.73m² in the NHANES (1999-2006) cohort, a large proportion is likely to 
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be subjects older than 65 years, without any other signs of kidney damage. These subjects 
would be considered disease-free with the age-adapted definition proposed above. Likewise, 
results from the MAREMAR (“Maladie Rénale Chronique au Maroc”) study crucially 
illustrate the important impact of an age-adapted definition on the CKD prevalence. Among 
the 10,524 subjects screened, 2.7% had a confirmed eGFR below 60 mL/min per 1.73m². 
However, almost half of the subjects with eGFR below 60 mL/min per 1.73m² had an eGFR 
above the third percentile of the population. These people, all older than 55 years and with 
normal dipstick analysis, would not be considered to have CKD with the age-adapted 
definition (here percentiles) and the estimated CKD prevalence based on GFR would decrease 
from 2.7% to 1.8%, a 33% decrease 97.  
The current fixed GFR threshold of 60 mL/min per 1.73m² not only results in over-diagnosis 
of CKD in the older adults, it may also lead to missed diagnoses of CKD in younger subjects 
without overt signs of kidney damage, who have a GFR below the lowest percentile for age, 
although above the fixed threshold of 60 mL/min per 1.73m². This group may include young 
people with low-nephron endowment, e.g. individuals born with a single kidney 145, those 
born pre-term 146, low-birth weight subjects, patients with Down syndrome 147 or young 
people with a past history of treatment with nephrotoxic drugs 148. Such people are at risk for 
developing progressive CKD over their remaining lifetime, and may suffer associated 
comorbidities and adverse events, including an increase in mortality 33,97,123,129. Notably, as 
there are limited curative therapies available yet, the treatment of CKD rests on the prevention 
of progressive kidney damage. The sooner young people with CKD are identified, the greater 
the chance that poor health outcomes may be prevented. In the MAREMAR study, the young 
people with a low for-age GFR represented 1.3% of the population 97. These persons remain 
unrecognized in most epidemiological studies that use a fixed GFR threshold of 60 mL/min 
per 1.73m² 97,123. Using SDS scores, percentiles or age-adapted staging in the definition of 
14 
 
CKD, these patients would be classified as having a disease. Further work seems necessary 
with a focus on long-term follow-up data to elucidate if this category of patients should be 
considered at risk for adverse renal or other disease-related outcomes.  
 
Conclusions 
Moving from a CKD definition with a fixed GFR threshold to a definition based on GFR 
adapted to age has several advantages: 
1. it takes into account the physiological age-related decline in GFR 
2. it fits with reference distributions of mGFR and eGFR in healthy subjects 
3. it is consistent with the observed associations between low GFR and prognosis 
4. it reconciles the two ways to define a disease: the distribution of lab results and the 
prognostic approach 
5. it facilitates the identification, evaluation and treatment of younger patients with 
GFR too low for their age  
6. it avoids over-diagnosis of CKD in the elderly 
 
An age-adapted definition of CKD will also lead to a much lower global CKD prevalence 
(perhaps by as much as 50%), particularly in the elderly. However, if we consider that: a) 
older subjects without increased urine ACR or other signs of kidney damage, usually have 
slightly decreased GFR; b) their GFR decrease is physiological; c) their GFR will on average 
remain stable (or could even improve) during follow-up; d) they have a mortality risk similar 
to those with higher GFR- then there are no reasons to consider such older subjects as 
suffering from disease and requiring investigations, referrals, and even therapeutic 
interventions with potential side effects 149. At an individual level, the application of a CKD 
status in older people (“D” meaning “disease”) can be source of unjustified stress. In some 
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countries, this diagnosis can also lead to adverse consequences in terms of insurance. The 
age-adapted CKD definition should eventually result in more appropriate attention and 
resources being directed to those who are at higher risk of adverse outcomes associated with 
CKD. 
 
 
 
 
 
 
 
Acknowledgments 
KJJ declared speaker honoraria from Fresenius and received grant support from ERA-EDTA. 
ES declared speaker honoraria from Fresenius Medical Care, Fresenius Kabi and Siemens 
Health Care. CW received grant from AHSC AFP Innovation Fund. TM declared speaker 
honoraria from Astellas. Norwegian evening summit. ASN, 2018. MvL declared speaker 
honoraria from Fresenius Medical Care. ADR declared royalties as “UpToDate” author on 
"Aging Kidney". The remaining authors declared no competing interests.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
References 
1.  KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of 
Chronic Kidney Disease. Kidney Int Suppl 3: 1–150, 2013 
2.  Delanaye P, Schaeffner E, Ebert N, Cavalier E, Mariat C, Krzesinski J-MM, Moranne 
O: Normal reference values for glomerular filtration rate: what do we really know? 
Nephrol Dial Transplant 27: 2664–2672, 2012 
3.  Poggio ED, Rule AD: Can we do better than a single estimated GFR threshold when 
screening for chronic kidney disease? Kidney Int 72: 534–536, 2007 
4.  Poggio ED, Rule AD: A critical evaluation of chronic kidney disease--should isolated 
reduced estimated glomerular filtration rate be considered a “disease”? Nephrol Dial 
Transplant 24: 698–700, 2009 
5.  Tonna SJ: Invited Commentary: Defining Incident Chronic Kidney Disease in 
Epidemiologic Study Settings. Am J Epidemiol 170: 425–427, 2009 
6.  Bash LD, Coresh J, Kottgen A, Parekh RS, Fulop T, Wang Y, Astor BC: Defining 
Incident Chronic Kidney Disease in the Research Setting: The ARIC Study. Am J 
Epidemiol 170: 414–424, 2009 
7.  Hsu C, Chertow GM: Chronic renal confusion: Insufficiency, failure, dysfunction, or 
disease. Am J Kidney Dis 36: 415–418, 2000 
8.  Hall YN, Himmelfarb J: The CKD Classification System in the Precision Medicine 
Era. Clin J Am Soc Nephrol 12: 19–21, 2016 
9.  Black C, van der Veer SN: Unlocking the Value of Variation in CKD Prevalence. J Am 
Soc Nephrol 27: 1874–7, 2016 
10.  Bauer C, Melamed ML, Hostetter TH: Staging of chronic kidney disease: time for a 
course correction. J Am Soc Nephrol 19: 844–846, 2008 
11.  Eknoyan G: Chronic kidney disease definition and classification: the quest for 
refinements. Kidney Int 72: 1183–5, 2007 
12.  Wesson LG: Renal hemodynamics in physiologic states. In: Physiology of the human 
kidney, edited by Wesson LG, pp 96–108, 1969 
13.  Poggio ED, Rule AD, Tanchanco R, Arrigain S, Butler RS, Srinivas T, Stephany BR, 
Meyer KH, Nurko S, Fatica RA, Shoskes DA, Krishnamurthi V, Goldfarb DA, Gill I, 
Schreiber Jr. MJ: Demographic and clinical characteristics associated with glomerular 
filtration rates in living kidney donors. Kidney Int 75: 1079–1087, 2009 
14.  Pottel H, Hoste L, Yayo E, Delanaye P: Glomerular filtration rate in healthy living 
potential kidney donors: a meta-analysis. Nephron 135: 105–119, 2017 
15.  Gaillard F, Courbebaisse M, Kamar N, Rostaing L, Del Bello A, Girerd S, Kessler M, 
Flamant M, Vidal-Petiot E, Peraldi M-N, Couzi L, Merville P, Malvezzi P, Janbon B, 
Moulin B, Caillard S, Gatault P, Büchler M, Maillard N, Dubourg L, Roquet O, 
Garrouste C, Legendre C, Delanaye P, Mariat C: The age-calibrated measured 
glomerular filtration rate improves living kidney donation selection process. Kidney Int 
94: 616–624, 2018 
16.  Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, 
Coresh J, Gansevoort RT, El-Nahas M, Eckardt KU, Kasiske BL, Tonelli M, 
Hemmelgarn B, Wang Y, Atkins RC, Polkinghorne KR, Chadban SJ, Shankar A, Klein 
R, Klein BEK, Wang H, Wang F, Zhang L, Liu L, Shlipak M, Sarnak MJ, Katz R, 
Fried LP, Jafar T, Islam M, Hatcher J, Poulter N, Chaturvedi N, Rothenbacher D, 
Brenner H, Raum E, Koenig W, Fox CS, Hwang SJ, Meigs JB, Cirillo M, Hallan S, 
Lydersen S, Holmen J, Shlipak M, Sarnak MJ, Katz R, Fried LP, Roderick P, Nitsch D, 
Fletcher A, Bulpitt C, Ohkubo T, Metoki H, Nakayama M, Kikuya M, Imai Y, Jassal 
SK, Barrett-Connor E, Bergstrom J, Warnock DG, Muntner P, Judd S, McClellan WM, 
Cushman M, Howard G, McClure L a., Jee SH, Kimm H, Yun JE, Wen CP, Wen SF, 
17 
 
Tsao CK, Tsai MK, Ärnlöv J, Auguste P, Veldhuis K, Camarata L, Thomas B, Manley 
T: Association of estimated glomerular filtration rate and albuminuria with all-cause 
and cardiovascular mortality in general population cohorts: a collaborative meta-
analysis. Lancet 375: 2073–2081, 2010 
17.  Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, 
Naimark D, Roderick P, Tonelli M, Wetzels JFM, Astor BC, Gansevoort RT, Levin A, 
Wen C-PP, Coresh J, Chronic Kidney Disease Prognosis Consortium  for the: Age and 
Association of Kidney Measures With Mortality and End-stage Renal Disease. JAMA 
308: 2349, 2012 
18.  Matsushita K, Ballew SH, Coresh J, Arima H, Ärnlöv J, Cirillo M, Ebert N, Hiramoto 
JS, Kimm H, Shlipak MG, Visseren FLJ, Gansevoort RT, Kovesdy CP, Shalev V, 
Woodward M, Kronenberg F, Chronic Kidney Disease Prognosis Consortium J, Arima 
H, Perkovic V, Grams ME, Sang Y, Schaeffner E, Martus P, Levin A, Djurdjev O, 
Tang M, Heine G, Seiler S, Zawada A, Emrich I, Sarnak M, Katz R, Brenner H, 
Schöttker B, Rothenbacher D, Saum K-U, Köttgen A, Schneider M, Eckardt K-U, 
Green J, Kirchner HL, Chang AR, Black C, Marks A, Prescott G, Clark L, Fluck N, Jee 
SH, Mok Y, Chodick G, Shalev V, Wetzels JFM, Blankestijn PJ, van Zuilen AD, Bots 
M, Peralta C, Hiromoto J, Katz R, Sarnak M, Bottinger E, Nadkarni GN, Ellis SB, 
Nadukuru R, Kenealy T, Elley CR, Collins JF, Drury PL, Bakker SJ, Heerspink HJL, 
Jassal SK, Bergstrom J, Ix JH, Barrett-Connor E, Kalantar-Zadeh K, Carrero JJ, 
Gasparini A, Qureshi AR, Barany P, Algra A, van der Graaf Y, Evans M, Segelmark 
M, Stendahl M, Schön S, Tangri N, Sud M, Naimark D, Lannfelt L, Larsson A, Hallan 
S, Levey AS, Chen J, Kwak L, Grams ME, Sang Y: Measures of chronic kidney 
disease and risk of incident peripheral artery disease: a collaborative meta-analysis of 
individual participant data. Lancet Diabetes Endocrinol 5: 718–728, 2017 
19.  Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, 
Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, 
de Jong PE, Wen CP, Nelson RG: Associations of kidney disease measures with 
mortality and end-stage renal disease in individuals with and without diabetes: a meta-
analysis. Lancet 380: 1662–1673, 2012 
20.  Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, 
Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn 
BR: Associations of estimated glomerular filtration rate and albuminuria with mortality 
and renal failure by sex: a meta-analysis. BMJ 346: f324, 2013 
21.  Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, 
Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de 
Jong PE, Astor BC: Associations of kidney disease measures with mortality and end-
stage renal disease in individuals with and without hypertension: a meta-analysis. 
Lancet 380: 1649–1661, 2012 
22.  Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, 
Landman GWD, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak 
M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, 
Sarnak M, Warnock DG, Woodward M, Ärnlöv J: Estimated glomerular filtration rate 
and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-
analysis of individual participant data. Lancet Diabetes Endocrinol 3: 514–25, 2015 
23.  Thomas B, Matsushita K, Abate KH, Al-Aly Z, Ärnlöv J, Asayama K, Atkins R, 
Badawi A, Ballew SH, Banerjee A, Barregård L, Barrett-Connor E, Basu S, Bello AK, 
Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero J-J, Chadban S, 
Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, 
Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, 
18 
 
Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, 
Khader Y, Khang Y-H, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey 
AS, Li Y, Lotufo P, El Razek HMA, Mendoza W, Metoki H, Mok Y, Muraki I, 
Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, 
Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum K-U, Sawhney M, Schöttker B, 
Shankar A, Shlipak M, Silva DAS, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, 
Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki MES, Naghavi 
M, Forouzanfar MH, Murray CJL, Coresh J, Vos T, Global Burden of Disease 2013 
GFR Collaborators, CKD Prognosis Consortium, Global Burden of Disease 
Genitourinary Expert Group: Global Cardiovascular and Renal Outcomes of Reduced 
GFR. J Am Soc Nephrol 28: 2167–2179, 2017 
24.  Wen CP, Matsushita K, Coresh J, Iseki K, Islam M, Katz R, McClellan W, Peralta C a, 
Wang H, de Zeeuw D, Astor BC, Gansevoort RT, Levey AS, Levin A: Relative risks of 
chronic kidney disease for mortality and end-stage renal disease across races are 
similar. Kidney Int 86: 1–9, 2014 
25.  van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, De JP, 
Gansevoort RT, van V D, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, 
de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, 
Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, 
Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen 
K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, 
Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, 
Manley T: Lower estimated glomerular filtration rate and higher albuminuria are 
associated with all-cause and cardiovascular mortality. A collaborative meta-analysis 
of high-risk population cohorts. Kidney Int 79: 1341–1352, 2011 
26.  Astor BC, Matsushita K, Gansevoort RT, van V D, Woodward M, Levey AS, Jong PE, 
Coresh J, Astor BC, Matsushita K, Gansevoort RT, van V D, Woodward M, Levey AS, 
de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, 
Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, 
Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, 
Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak 
M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi 
G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, De ZD, Rossing P, Parving HH, 
Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T: Lower estimated 
glomerular filtration rate and higher albuminuria are associated with mortality and end-
stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. 
Kidney Int 79: 1331–1340, 2011 
27.  Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, 
Jong PE, Coresh J, Gansevoort RT, Matsushita K, van V D, Astor BC, Woodward M, 
Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, 
Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Wang Y, Atkins RC, 
Polkinghorne KR, Chadban SJ, Shankar A, Klein R, Klein BE, Sacks F, Curhan G, 
Shlipak M, Sarnak MJ, Katz R, Fried LP, Hallan S, Lydersen S, Holmen J, Lee BJ, 
Ishani A, Neaton J, Svendsen K, Iseki K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson 
RG, Knowler WC, Auguste P, Veldhuis K, Camarata L, Thomas B, Manley T: Lower 
estimated GFR and higher albuminuria are associated with adverse kidney outcomes in 
both general and high-risk populations. A collaborative meta-analysis of general and 
high-risk population cohorts. Kidney Int 80: 93–104, 2011 
28.  Hui X, Matsushita K, Sang Y, Ballew SH, Fülöp T, Coresh J: CKD and cardiovascular 
disease in the Atherosclerosis Risk in Communities (ARIC) study: interactions with 
19 
 
age, sex, and race. Am J Kidney Dis 62: 691–702, 2013 
29.  Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–
1305, 2004 
30.  Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, 
Levey AS: A predictive model for progression of chronic kidney disease to kidney 
failure. JAMA 305: 1553–1559, 2011 
31.  Delanaye P, Glassock RJ, Pottel H, Rule AD: An Age-Calibrated Definition of Chronic 
Kidney Disease: Rationale and Benefits. Clin Biochem Rev 37: 17–26, 2016 
32.  Glassock R, Denic A, Rule AD: When kidneys get old: an essay on nephro-geriatrics. J 
Bras Nefrol 39: 59–64, 2017 
33.  Glassock RJ: Con: Thresholds to define chronic kidney disease should not be age 
dependent. Nephrol Dial Transplant 29: 774–779, 2014 
34.  Denic A, Glassock RJ, Rule AD: Structural and functional changes with the aging 
kidney. Adv Chronic Kidney Dis 23: 19–28, 2016 
35.  Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, 
Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the 
elderly. Kidney Int 63: 1121–1129, 2003 
36.  O’Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, Mehta K, Steinman 
MA, Borzecki A, Walter LC: Mortality risk stratification in chronic kidney disease: 
one size for all ages? J Am Soc Nephrol 17: 846–853, 2006 
37.  Maaravi Y, Bursztyn M, Hammerman-Rozenberg R, Stessman J: Glomerular filtration 
rate estimation and mortality in an elderly population. QJM 100: 441–9, 2007 
38.  Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J: Association of 
kidney function and albuminuria with cardiovascular mortality in older vs younger 
individuals: The HUNT II Study. Arch Intern Med 167: 2490–2496, 2007 
39.  Brantsma AH, Bakker SJL, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, 
PREVEND Study Group: Cardiovascular and renal outcome in subjects with K/DOQI 
stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol 
Dial Transplant 23: 3851–8, 2008 
40.  Hwang S-J, Lin M-Y, Chen H-C, Hwang S-C, Yang W-C, Hsu C-C, Chiu H-C, Mau L-
W: Increased risk of mortality in the elderly population with late-stage chronic kidney 
disease: a cohort study in Taiwan. Nephrol Dial Transplant 23: 3192–3198, 2008 
41.  Roderick PJ, Atkins RJ, Smeeth L, Mylne A, Nitsch DD, Hubbard RB, Bulpitt CJ, 
Fletcher AE: CKD and mortality risk in older people: a community-based population 
study in the United Kingdom. Am J Kidney Dis 53: 950–960, 2009 
42.  van der Velde M, Bakker SJL, De Jong PE, Gansevoort RT: Influence of age and 
measure of eGFR on the association between renal function and cardiovascular events. 
Clin J Am Soc Nephrol 5: 2053–2059, 2010 
43.  Muntner P, Bowling CB, Gao L, Rizk D, Judd S, Tanner RM, McClellan W, Warnock 
DG: Age-specific association of reduced estimated glomerular filtration rate and 
albuminuria with all-cause mortality. Clin J Am Soc Nephrol 6: 2200–2207, 2011 
44.  Stengel B, Metzger M, Froissart M, Rainfray M, Berr C, Tzourio C, Helmer C: 
Epidemiology and prognostic significance of chronic kidney disease in the elderly--the 
Three-City prospective cohort study. Nephrol Dial Transplant 26: 3286–3295, 2011 
45.  Van Pottelbergh G, Vaes B, Adriaensen W, Matheï C, Legrand D, Wallemacq P, 
Degryse JM: The glomerular filtration rate estimated by new and old equations as a 
predictor of important outcomes in elderly patients. BMC Med 12: 27, 2014 
46.  Oh SW, Kim S, Na KY, Kim KW, Chae D-W, Chin HJ: Glomerular filtration rate and 
proteinuria: association with mortality and renal progression in a prospective cohort of 
20 
 
a community-based elderly population. PloS One 9: e94120, 2014 
47.  Minutolo R, Lapi F, Chiodini P, Simonetti M, Bianchini E, Pecchioli S, Cricelli I, 
Cricelli C, Piccinocchi G, Conte G, De NL: Risk of ESRD and death in patients with 
CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol 
9: 1586–1593, 2014 
48.  Malmgren L, McGuigan FE, Berglundh S, Westman K, Christensson A, Akesson K: 
Declining Estimated Glomerular Filtration Rate and Its Association with Mortality and 
Comorbidity Over 10 Years in Elderly Women. Nephron 130: 245–255, 2015 
49.  Chowdhury EK, Langham RG, Owen A, Krum H, Wing LMH, Nelson MR, Reid CM, 
Second Australian National Blood Pressure Study Management Committeem: 
Comparison of predictive performance of renal function estimation equations for all-
cause and cardiovascular mortality in an elderly hypertensive population. Am J 
Hypertens 28: 380–6, 2015 
50.  Nagai K, Sairenchi T, Irie F, Watanabe H, Ota H, Yamagata K: Relationship between 
Estimated Glomerular Filtration Rate and Cardiovascular Mortality in a Japanese 
Cohort with Long-Term Follow-Up. PloS One 11: e0156792, 2016 
51.  Corsonello A, Pedone C, Bandinelli S, Ferrucci L, Antonelli Incalzi R: Predicting 
survival of older community-dwelling individuals according to five estimated 
glomerular filtration rate equations: The InChianti study. Geriatr Gerontol Int 18: 607–
614, 2018 
52.  Wu J, Jia J, Li Z, Pan H, Wang A, Guo X, Wu S, Zhao X: Association of estimated 
glomerular filtration rate and proteinuria with all-cause mortality in community-based 
population in China: A Result from Kailuan Study. Sci Rep 8: 2157, 2018 
53.  O’Hare AM, Hailpern SM, Pavkov ME, Rios-Burrows N, Gupta I, Maynard C, Todd-
Stenberg J, Rodriguez RA, Hemmelgarn BR, Saran R, Williams DE: Prognostic 
implications of the urinary albumin to creatinine ratio in veterans of different ages with 
diabetes. Arch Intern Med 170: 930–6, 2010 
54.  Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann 
JF, Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: 
epidemiology, mechanisms, and prevention. Lancet 382: 339–352, 2013 
55.  Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW: Chronic Kidney 
Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study. 
PLoS Med 13: e1002128, 2016 
56.  Raymond NT, Zehnder D, Smith SC, Stinson JA, Lehnert H, Higgins RM: Elevated 
relative mortality risk with mild-to-moderate chronic kidney disease decreases with 
age. Nephrol Dial Transplant 22: 3214–3220, 2007 
57.  Wyatt CM: A rose by any other name: is stage 3a chronic kidney disease really a 
disease? Kidney Int 91: 6–8, 2017 
58.  Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M’rad MB, 
Jacquot C, Houillier P, Stengel B, Fouqueray B: Timing of onset of CKD-related 
metabolic complications. J Am Soc Nephrol 20: 164–171, 2009 
59.  Drawz PE, Babineau DC, Rahman M: Metabolic Complications in Elderly Adults with 
Chronic Kidney Disease. J Am Geriatr Soc 60: 310–315, 2012 
60.  Bowling CB, Muntner P, Sawyer P, Sanders PW, Kutner N, Kennedy R, Allman RM: 
Community mobility among older adults with reduced kidney function: a study of life-
space. Am J Kidney Dis 63: 429–36, 2014 
61.  Fried LF, Lee JS, Shlipak M, Chertow GM, Green C, Ding J, Harris T, Newman AB: 
Chronic Kidney Disease and Functional Limitation in Older People: Health, Aging and 
Body Composition Study. J Am Geriatr Soc 54: 750–756, 2006 
62.  Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, Textor SC, Stegall 
21 
 
MD: The association between age and nephrosclerosis on renal biopsy among healthy 
adults. Ann Intern Med 152: 561–567, 2010 
63.  Denic A, Lieske JC, Chakkera HA, Poggio ED, Alexander MP, Singh P, Kremers WK, 
Lerman LO, Rule AD: The Substantial Loss of Nephrons in Healthy Human Kidneys 
with Aging. J Am Soc Nephrol 28: 313–320, 2017 
64.  Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP, Poggio E, 
Glassock RJ, Rule AD: Single-Nephron Glomerular Filtration Rate in Healthy Adults. 
N Engl J Med 376: 2349–2357, 2017 
65.  Tan JC, Busque S, Workeneh B, Ho B, Derby G, Blouch KL, Sommer FG, Edwards B, 
Myers BD: Effects of aging on glomerular function and number in living kidney 
donors. Kidney Int 78: 686–692, 2010 
66.  Hommos MS, Zeng C, Liu Z, Troost JP, Rosenberg AZ, Palmer M, Kremers WK, 
Cornell LD, Fervenza FC, Barisoni L, Rule AD: Global glomerulosclerosis with 
nephrotic syndrome; the clinical importance of age adjustment. Kidney Int 93: 1175–
1182, 2018 
67.  Srivastava A, Palsson R, Kaze AD, Chen ME, Palacios P, Sabbisetti V, Betensky RA, 
Steinman TI, Thadhani RI, McMahon GM, Stillman IE, Rennke HG, Waikar SS: The 
Prognostic Value of Histopathologic Lesions in Native Kidney Biopsy Specimens: 
Results from the Boston Kidney Biopsy Cohort Study. J Am Soc Nephrol 29: 2213–
2224, 2018 
68.  Yayo E, Ayé M, Yao C, Gnionsahé A, Attoungbré M-L, Cavalier E, Pottel H, Monnet 
D, Delanaye P: Measured (and estimated) glomerular filtration rate: reference values in 
West Africa. Nephrol Dial Transplant 33: 1176–1180, 2018 
69.  Hogeman O: Normal Individuals. Acta Med Scand Suppl 131: 99–108, 1948 
70.  Bucht H: Studies on renal function in man; with special reference to glomerular 
filtration and renal plasma flow in pregnancy. Scand J Clin Lab Invest 3: 1–64, 1951 
71.  Slack TK, Wilson DM: Normal renal function: CIN and CPAH in healthy donors 
before and after nephrectomy. Mayo Clin Proc 51: 296–300, 1976 
72.  Landahl S, Aurell M, Jagenburg R: Glomerular filtration rate at the age of 70 and 75. J 
Clin Exp Gerontol 3: 29–45, 1981 
73.  Granerus G, Aurell M: Reference values for 51Cr-EDTA clearance as a measure of 
glomerular filtration rate. Scand J Clin Lab Invest 41: 611–616, 1981 
74.  Hamilton D, Riley P, Miola U, Mousa D, Popovich W, al Khader A: Total plasma 
clearance of 51Cr-EDTA: variation with age and sex in normal adults. Nucl Med 
Commun 21: 187–192, 2000 
75.  Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, Larson TS: 
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 43: 
112–119, 2004 
76.  Grewal GS, Blake GM: Reference data for 51Cr-EDTA measurements of the 
glomerular filtration rate derived from live kidney donors. Nucl Med Commun 26: 61–
65, 2005 
77.  Barai S, Bandopadhayaya GP, Patel CD, Rathi M, Kumar R, Bhowmik D, Gambhir S, 
Singh NG, Malhotra A, Gupta KD: Do healthy potential kidney donors in india have an 
average glomerular filtration rate of 81.4 ml/min? Nephron Physiol 101: 21–26, 2005 
78.  Berg UB: Differences in decline in GFR with age between males and females. 
Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol 
Dial Transplant 21: 2577–2582, 2006 
79.  Jafar TH, Islam M, Jessani S, Bux R, Inker LA, Mariat C, Levey AS: Level and 
determinants of kidney function in a South Asian population in Pakistan. Am J Kidney 
Dis 58: 764–772, 2011 
22 
 
80.  Ma YC, Zuo L, Chen L, Su ZM, Meng S, Li JJ, Zhang CL, Wang HY: Distribution of 
measured GFR in apparently healthy Chinese adults. Am J Kidney Dis 56: 420–421, 
2010 
81.  Soares AA, Prates AB, Weinert LS, Veronese FV, de Azevedo MJ, Silveiro SP: 
Reference values for glomerular filtration rate in healthy Brazilian adults. BMC 
Nephrol 14: 54, 2013 
82.  Peters AM, Perry L, Hooker CA, Howard B, Neilly MD, Seshadri N, Sobnack R, Irwin 
A, Snelling H, Gruning T, Patel NH, Lawson RS, Shabo G, Williams N, Dave S, 
Barnfield MC: Extracellular fluid volume and glomerular filtration rate in 1878 healthy 
potential renal transplant donors: effects of age, gender, obesity and scaling. Nephrol 
Dial Transplant 27: 1429–1437, 2012 
83.  Holness JL, Fleming JS, Malaroda AL, Warwick JM: (99m)Tc-DTPA volume of 
distribution, half-life and glomerular filtration rate in normal adults. Nucl Med 
Commun 34: 1005–1014, 2013 
84.  De Santo NG, Capasso G, Anastasio P, Coppola S, Policastro M, Bellini L, Massimo 
L, Pollastro RM, Papalia T, Di Leo VA: Renal functional reserve. Child Nephrol Urol 
11: 140–5, 1991 
85.  Davies DF, Shock NW: Age changes in glomerular filtration rate, effective renal 
plasma flow, and tubular excretory capacity in adult males. J Clin Invest 29: 496–507, 
1950 
86.  Shock NW: Kidney function tests in aged males. Geriatrics 1: 232–239, 1946 
87.  Horio M, Yasuda Y, Kaimori J, Ichimaru N, Isaka Y, Takahara S, Nishi S, Uchida K, 
Takeda A, Hattori R, Kitada H, Tsuruya K, Imai E, Takahashi K, Watanabe T, Matsuo 
S: Performance of the Japanese GFR equation in potential kidney donors. Clin Exp 
Nephrol 16: 415–20, 2012 
88.  Hoang K, Tan JC, Derby G, Blouch KL, Masek M, Ma I, Lemley K V, Myers BD: 
Determinants of glomerular hypofiltration in aging humans. Kidney Int 64: 1417–1424, 
2003 
89.  Teo BW, Xu H, Koh YY, Li J, Subramanian S, Sinha AK, Shuter B, Toh QC, Sethi S, 
Lee EJ: Glomerular filtration rates in healthy Asians without kidney disease. 
Nephrology (Carlton) 19: 72–79, 2014 
90.  den Bakker E, Gemke RJBJ, Bökenkamp A: Endogenous markers for kidney function 
in children: a review. Crit Rev Clin Lab Sci 55: 163–183, 2018 
91.  Pottel H, Delanaye P, Weekers L, Selistre L, Goffin K, Gheysens O, Dubourg L: Age-
dependent reference intervals for estimated and measured glomerular filtration rate. 
Clin Kidney J 10: 545–551, 2017 
92.  Back SE, Ljungberg B, Nilsson-Ehle I, Borga O, Nilsson-Ehle P: Age dependence of 
renal function: clearance of iohexol and p-amino hippurate in healthy males. Scand J 
Clin Lab Invest 49: 641–646, 1989 
93.  Pottel H, Hoste L, Dubourg L, Ebert N, Schaeffner ES, Eriksen BO, Rule AD, Turner 
STT, Glassock RJRJ, Mariat C, Martens F, Delanaye P, Melsom T, Lamb EJ, Rule AD, 
Turner STT, Glassock RJRJ, De Souza V, Selistre L, Mariat C, Martens F, Delanaye P: 
A new estimating glomerular filtration rate equation for the full age spectrum. Nephrol 
Dial Transplant 31: 798–806, 2016 
94.  Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro III AF, Feldman HI, Kusek 
JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate 
glomerular filtration rate. Ann Intern Med 150: 604–612, 2009 
95.  Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MKK, 
Schuchardt M, Tölle M, Ziebig R, van der Giet M, Martus P, Tolle M, Ziebig R, van 
der Giet M, Martus P, Tölle M, Ziebig R, van der Giet M, Martus P: Two novel 
23 
 
equations to estimate kidney function in persons aged 70 years or older. Ann Intern 
Med 157: 471–481, 2012 
96.  Baba M, Shimbo T, Horio M, Ando M, Yasuda Y, Komatsu Y, Masuda K, Matsuo S, 
Maruyama S: Longitudinal Study of the Decline in Renal Function in Healthy Subjects. 
Plos One 10: e0129036, 2015 
97.  Benghanem Gharbi M, Elseviers M, Zamd M, Belghiti Alaoui A, Benahadi N, 
Trabelssi EH, Bayahia R, Ramdani B, De Broe ME: Chronic kidney disease, 
hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid 
“over”- and “under”-diagnosis of CKD. Kidney Int 89: 1363–1371, 2016 
98.  van den Brand JA, van Boekel GA, Willems HL, Kiemeney LA, Den HM, Wetzels JF, 
den Heijer M, Wetzels JF: Introduction of the CKD-EPI equation to estimate 
glomerular filtration rate in a Caucasian population. Nephrol Dial Transplant 26: 
3176–3181, 2011 
99.  Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, Den HM: Age- and gender-
specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical 
Study. Kidney Int 72: 632–637, 2007 
100.  Elseviers MM, Verpooten GA, De Broe ME, De Backer GG: Interpretation of 
creatinine clearance. Lancet 1: 457, 1987 
101.  Ebert N, Jakob O, Gaedeke J, van der Giet M, Kuhlmann MK, Martus P, Mielke N, 
Schuchardt M, Tölle M, Wenning V, Schaeffner ES: Prevalence of reduced kidney 
function and albuminuria in older adults: the Berlin Initiative Study. Nephrol Dial 
Transplant 32: 997–1005, 2017 
102.  Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal 
function with age. J Am Geriatr Soc 33: 278–285, 1985 
103.  Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, Kumar R, 
Posselt AA, Pesavento TE, Rabb H, Steffes MW, Snyder JJ, Weir MR: A prospective 
controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis 66: 
114–124, 2015 
104.  Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW: The effect of age on creatinine 
clearance in men: a cross-sectional and longitudinal study. J Gerontol 31: 155–163, 
1976 
105.  Cohen E, Nardi Y, Goldberg E, Milo G, Garthy M, Krause I: A longitudinal assessment 
of the natural rate of decline in renal function with age. J Nephrol 27: 635–641, 2014 
106.  Hollenberg NK, Rivera A, Meinking T, Martinez G, McCullough M, Passan D, Preston 
M, Taplin D, Vicaria-Clement M: Age, renal perfusion and function in island-dwelling 
indigenous Kuna Amerinds of Panama. Nephron 82: 131–138, 1999 
107.  O’Sullivan ED, Hughes J, Ferenbach DA: Renal Aging: Causes and Consequences. J 
Am Soc Nephrol 28: 407–420, 2017 
108.  Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, 
Hishida A, Matsuo S: Slower decline of glomerular filtration rate in the Japanese 
general population: a longitudinal 10-year follow-up study. Hypertens Res 31: 433–41, 
2008 
109.  Lauretani F, Semba RD, Bandinelli S, Miller ER, Ruggiero C, Cherubini A, Guralnik 
JM, Ferrucci L: Plasma polyunsaturated fatty acids and the decline of renal function. 
Clin Chem 54: 475–81, 2008 
110.  Bolignano D, Mattace-Raso F, Sijbrands EJG, Zoccali C: The aging kidney revisited: a 
systematic review. Ageing Res Rev 14: 65–80, 2014 
111.  Jiang S, Sun X, Gu H, Chen Y, Xi C, Qiao X, Chen X: Age-related change in kidney 
function, its influencing factors, and association with asymptomatic carotid 
atherosclerosis in healthy individuals--a 5-year follow-up study. Maturitas 73: 230–8, 
24 
 
2012 
112.  Delanaye P, Glassock RJ: Glomerular Filtration Rate and Aging: Another Longitudinal 
Study - A Long Time Coming! Nephron 131: 1–4, 2015 
113.  Eriksen BO, Ingebretsen OC: The progression of chronic kidney disease: a 10-year 
population-based study of the effects of gender and age. Kidney Int 69: 375–382, 2006 
114.  Eriksen BO, Stefansson VTN, Jenssen TG, Mathisen UD, Schei J, Solbu MD, 
Wilsgaard T, Melsom T: Elevated blood pressure is not associated with accelerated 
glomerular filtration rate decline in the general non-diabetic middle-aged population. 
Kidney Int 90: 404–410, 2016 
115.  Rule AD, Glassock RJ: Chronic kidney disease: Classification of CKD should be about 
more than prognosis. Nat Rev Nephrol 9: 697–8, 2013 
116.  Glassock RJ, Winearls C: An epidemic of chronic kidney disease: fact or fiction? 
Nephrol Dial Transplant 23: 1117–1121, 2008 
117.  Delanaye P, Cavalier E: Staging chronic kidney disease and estimating glomerular 
filtration rate: an opinion paper about the new international recommendations. Clin 
Chem Lab Med 51: 1911–1917, 2013 
118.  Glassock RJ, Rule AD: The implications of anatomical and functional changes of the 
aging kidney: with an emphasis on the glomeruli. Kidney Int 82: 270–277, 2012 
119.  Wetzels JF, Willems HL, den Heijer M: Age- and gender-specific reference values of 
estimated glomerular filtration rate in a Caucasian population: Results of the Nijmegen 
Biomedical Study. Kidney Int 73: 657–658, 2008 
120.  Ellam T, Twohig H, Khwaja A: Chronic kidney disease in elderly people: disease or 
disease label? BMJ 352: h6559, 2016 
121.  Moynihan R, Glassock R, Doust J: Chronic kidney disease controversy: how 
expanding definitions are unnecessarily labelling many people as diseased. BMJ 347: 
f4298, 2013 
122.  Botev R, Mallie JP, Wetzels JF, Couchoud C, Schuck O: The Clinician and Estimation 
of Glomerular Filtration Rate by Creatinine-based Formulas: Current Limitations and 
Quo Vadis. Clin J Am Soc Nephrol 6: 937–950, 2011 
123.  De Broe ME, Gharbi MB, Zamd M, Elseviers M: Why overestimate or underestimate 
chronic kidney disease when correct estimation is possible? Nephrol Dial Transplant 
32: ii136-ii141, 2017 
124.  Roderick PJ, Atkins RJ, Smeeth L, Nitsch DM, Hubbard RB, Fletcher AE, Flectcher 
AE, Bulpitt CJ: Detecting chronic kidney disease in older people; what are the 
implications? Age Ageing 37: 179–86, 2008 
125.  Boele-Schutte E, Gansevoort RT: Measured GFR: not a gold, but a gold-plated 
standard. Nephrol Dial Transplant 32: ii180-ii184, 2017 
126.  Soveri I, Berg UB, Björk J, Elinder C-GG, Grubb A, Mejare I, Sterner G, Bäck S-E, 
Bjork J, Elinder C-GG, Grubb A, Mejare I, Sterner G, Back SE: Measuring GFR: a 
systematic review. Am J Kidney Dis 64: 411–424, 2014 
127.  Björk J, Bäck SE, Ebert N, Evans M, Grubb A, Hansson M, Jones I, Lamb EJ, Martus 
P, Schaeffner E, Sjöström P, Nyman U: GFR estimation based on standardized 
creatinine and cystatin C: a European multicenter analysis in older adults. Clin Chem 
Lab Med 56: 422–435, 2018 
128.  Glassock R, Delanaye P, El Nahas M: An Age-Calibrated Classification of Chronic 
Kidney Disease. JAMA 314: 559–560, 2015 
129.  Pottel H, Hoste L, Delanaye P: Abnormal glomerular filtration rate in children, 
adolescents and young adults starts below 75 mL/min/1.73 m2. Pediatr Nephrol 30: 
821–828, 2015 
130.  Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, Chen J, He J: A 
25 
 
systematic analysis of worldwide population-based data on the global burden of 
chronic kidney disease in 2010. Kidney Int 88: 950–957, 2015 
131.  Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR: 
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-
Analysis. PloS One 11: e0158765, 2016 
132.  Gambaro G, Yabarek T, Graziani MS, Gemelli A, Abaterusso C, Frigo AC, 
Marchionna N, Citron L, Bonfante L, Grigoletto F, Tata S, Ferraro PM, Legnaro A, 
Meneghel G, Conz P, Rizzotti P, D’Angelo A, Lupo A, INCIPE Study Group: 
Prevalence of CKD in Northeastern Italy: Results of the INCIPE Study and 
Comparison with NHANES. Clin J Am Soc Nephrol 5: 1946–1953, 2010 
133.  De Nicola L, Donfrancesco C, Minutolo R, Lo NC, Palmieri L, De CA, Iacoviello L, 
Zoccali C, Gesualdo L, Conte G, Vanuzzo D, Giampaoli S: Prevalence and 
cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008-12 
National Health Examination Survey. Nephrol Dial Transplant 30: 806–814, 2015 
134.  Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey 
AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 
2007 
135.  Zdrojewski Ł, Zdrojewski T, Rutkowski M, Bandosz P, Król E, Wyrzykowski B, 
Rutkowski B: Prevalence of chronic kidney disease in a representative sample of the 
Polish population: results of the NATPOL 2011 survey. Nephrol Dial Transplant 31: 
433–9, 2016 
136.  Zdrojewski Ł, Król E, Rutkowski B, Piotrowski W, Pająk A, Drygas W, Zdrojewski T: 
Chronic kidney disease in Polish elderly population aged 75+: results of the WOBASZ 
Senior Survey. Int Urol Nephrol 49: 669–676, 2017 
137.  Wen CH, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, 
Sung PK, Hsu YH, Wen SF: All-cause mortality attributable to chronic kidney disease: 
a prospective cohort study based on 462293 adults in Taiwan. Lancet 371: 2173–2182, 
2008 
138.  Hallan SI, Øvrehus MA, Romundstad S, Rifkin D, Langhammer A, Stevens PE, Ix JH: 
Long-term trends in the prevalence of chronic kidney disease and the influence of 
cardiovascular risk factors in Norway. Kidney Int 90: 665–673, 2016 
139.  Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai C-Y, Floyd T, 
Al-Aly Z: Analysis of the Global Burden of Disease study highlights the global, 
regional, and national trends of chronic kidney disease epidemiology from 1990 to 
2016. Kidney Int 94: 567–581, 2018 
140.  Brück K, Stel VS, Gambaro G, Hallan S, Volzke H, Arnlov J, Kastarinen M, Guessous 
I, Vinhas J, Stengel B, Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, 
Bello AK, Ferrieres J, Palmieri L, Browne G, Capuano V, Van Biesen W, Zoccali C, 
Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner C, Jager KJ: 
CKD Prevalence Varies across the European General Population. J Am Soc Nephrol 
27: 2135–2147, 2016 
141.  Pottel H, Delanaye P, Schaeffner ESEES, Dubourg L, Eriksen BOBO, Toralf M, Lamb 
EJEJ, Rule AD, Turner STSTST, Glassock RJRJ, De Souza V, Selistre L, Goffin K, 
Pauwels S, Mariat C, Flamant M, Ebert N, Melsom T, Lamb EJEJ, Rule AD, Turner 
STSTST, Glassock RJRJ, De Souza V, Selistre L, Goffin K, Pauwels S, Mariat C, 
Flamant M, Ebert N: Estimating Glomerular Filtration Rate for the Full Age Spectrum 
from Serum creatinine and cystatin C. Nephrol Dial Transplant 32: 497–507, 2017 
142.  Wen C, Wen S, Tsai S, Cheng T, Tsai M: Chronic kidney disease in Taiwan – Authors’ 
reply. Lancet 372: 1950–1951, 2008 
143.  McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW: Risk profile in chronic kidney 
26 
 
disease stage 3: older versus younger patients. Nephron Clin Pract 119: c269-76, 2011 
144.  James MT, Hemmelgarn BR, Wiebe N, Pannu N, Manns BJ, Klarenbach SW, Tonelli 
M: Glomerular filtration rate, proteinuria, and the incidence and consequences of acute 
kidney injury: a cohort study. Lancet 376: 2096–2103, 2010 
145.  Schreuder MF: Life with one kidney. Pediatric Nephrology 33: 595–604, 2018 
146.  Abitbol CL, DeFreitas MJ, Strauss J: Assessment of kidney function in preterm infants: 
lifelong implications. Pediatr Nephrol 31: 2213–2222, 2016 
147.  Yamakawa S, Nagai T, Uemura O: Down syndrome and mild kidney dysfunction. 
Pediatr Nephrol 60: 391–393, 2018 
148.  Ellis MJ, Parikh CR, Inrig JK, Kambay M, Patel UD, Patel UD: Chronic Kidney 
Disease After Hematopoietic Cell Transplantation: A Systematic Review. Am J 
Transplant 8: 2378–2390, 2008 
149.  O’Hare AM, Hotchkiss JR, Kurella TM, Larson EB, Hemmelgarn BR, Batten A, Do 
TP, Covinsky KE: Interpreting treatment effects from clinical trials in the context of 
real-world risk information: end-stage renal disease prevention in older adults. JAMA 
Intern Med 174: 391–397, 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Legend 
Table 1:  Current CKD staging according to glomerular filtration rate (GFR) and urine 
albumin-to-creatinine ratio (ACR). 
Table2: Characteristics of studies that investigated outcomes in relation to GFR in general 
populations 
Table3: Findings of studies that investigated outcomes in relation to GFR in general 
populations 
Figure 1: Hazard ratio for mortality when the reference group is the one with the lowest risk. 
eGFR ranges are within the brackets (low risk) and are not significantly different from the 
reference group (from 34) 
Figure 2: Examples of interpretation of GFR (here GFR estimated using the FAS equation 
but the same can be applied to measured GFR or eGFR using other estimating equations) 
according to age and normal percentiles. The red circle corresponds to FAS = 48mL/min per 
1.73m² (Serum creatinine (SCr) = 1.3 mg/dL corresponds to (SCr/Q = 1.3/0.9 = 1.44 > 1.33) 
and the green circle corresponds to FAS = 58 mL/min per 1.73m² (SCr = 1.1 mg/dL 
corresponds to SCr/Q = 1.22 < 1.33). These results are abnormally low and normal predicted 
eGFR-FAS results with the age-adapted staging, respectively.  
‘Dark’ green shaded area corresponds to reference intervals for mGFR ± SD and symmetrical 
limits for FAS based on SCr/Q = 1 (middle line) and SCr/Q = 1.33 (lower limit) [14, 18]. 
‘Light’ green area corresponds to the upper limit for FAS, based on SCr/Q = 0.67. The 
interval [0.67 – 1.33] is considered the reference interval for SCr/Q. 
 
Figure 3: GFR cut-off values and percentiles according to age (here percentiles of estimated 
GFR calculated using the FAS equation). The black bold line represents an age adapted 
threshold for CKD: 75 mL/min per 1.73m² for age below 40 years, 60 mL/min per 1.73m² for 
age between 40 and 65 years, and 45 mL/min per 1.73m² for age above 65 years. The dashed 
bold line represents the median (50th, percentile 50) and the black thin solid lines represent the 
97.5th and 2.5th percentiles. The grey zone is considered as below the normal reference 
intervals for GFR (<2.5th percentile). 
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Table 1 
GFR category GFR (mL/min per 1.73m²)  
G1 ≥90 
G2 60-89 
G3a 45-59 
G3b 30-44 
G4 15-29 
G5 <15 
 
ACR category Urine ACR (mg/g) 
A1 <30 
A2 30-300 
A3 >300 
ACR: Albumin-to-Creatinine Ratio, GFR: Glomerular Filtration Rate 
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Table 2 
Author [ref] Study name Country Time period of 
data collection 
Number of 
subjects, N 
Age (in years; mean±SD 
/median (range) and other 
potentailly relevant 
characteristics  
Follow-up time 
(years) 
Clinical cohort/ 
General 
population 
Manjunath et al. 35 Cardiovascular 
Health Study 
USA 1989-1990 4,893 73.4 (mean) 5.05 GP 
Go et al.29 Kaiser 
Permanente Renal 
Registry 
USA 1996-2000 1,120,295 52.2± 16.3 (mean±SD)   2.84 (median) 
1.65-4.01 (IQR) 
GP (health insurer) 
O’Hare et al. 36 Dept. of Veterans 
Affairs 
USA 2001-2002 2,583,911 63.6±14(mean±SD) 
95% men 
3.17 ± 0.62 
(mean±SD) 
GP (health care 
provider) 
Maaravi et al. 37 Jerusalem 
Seventy Year 
Olds Longitudinal 
Study 
Israel 1990-1991 441 70 (all) 12 (maximum) GP 
Hallan et al. 38 HUNT II Norway 1995-1997 9,709 All with DM or treated HT plus 
5% random sample. 
DM/HT age 65.9± 11.9 
(mean±SD); 
Random non-DM/HT age 
49.6±16.0 (mean±SD).  
 
8.3 (median) GP (health survey) 
Population based, 
but in fact a ‘high-
risk’ study 
population. 
Raymond et al.56 NA United 
Kingdom 
2000-2003 106,366 57.7± 19.1 (mean±SD) 3 (maximum) GP 
Brantsma et al. 39 PREVEND Netherlands 1997-1998 8,495 49.2±12.7 (mean±SD)   7.5 (median) 
6.9-7.8 (IQR) 
GP 
Oversampling of 
individuals with 
elevated ACR 
levels. 
Hwang et al. 40 Elderly Health 
Examination 
Program 
Taiwan 2002-2004 35,529 75.7± 5.3 (mean±SD)   From 2.6±0.3 
(mean±SD) for eGFR 
≥ 60 mL/min to 
2.3±0.7 (mean±SD) 
for stage 5 
GP 
Roderick et al. 41 MRC GP research 
framework 
UK 1994-1999 13,177 80.2 (median) (IQR 6.9) 7.3 (median) 
(IQR 5) 
GP (primary care) 
Van der Velde et al. 42 PREVEND Netherlands 1997-1998 8,047 49±13(mean±SD) 
 
7.0±1.6 (mean±SD) GP 
Oversampling of 
individuals with 
elevated ACR 
levels. 
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Muntner et al.43 REGARDS USA 2003-2007 24,350 ≥ 45 4.5 (median) GP 
Oversampling of 
African Americans. 
Stengel et al. 44 Three-City France 1999-2001 8,705 74.3±5.5 (mean±SD)   6 (maximum) GP 
Van Pottelbergh et al. 
45 
BELFRAIL Belgium 2008-2009 539 84.7±3.6 (mean±SD)   2.9±0.3 GP (primary care) 
Oh et al. 46 KloSHA Korea 2005-2006 949 75.8±9.0 (mean±SD)   5.3±1.4 (mean±SD)   GP 
Minutolo et al.47 Health 
Search/Cegedim 
Strategic Data 
Longitudinal 
Patient Database 
Italy 2003-2005 30,326 71.0± 11.0 (mean±SD) 7.2 (median) 4.7-7.7 
(IQR) 
GP (primary care) 
Population without 
nephrology 
consultation at 
baseline. 
Malmgren et al.48 NA Sweden unknown 1,011 75.2 ± 0.2(mean±SD) 
100% women 
10 GP 
Chowdhury et al. 49 ANBP2 Australia NA 6,083 71.9±4.9 (mean±SD)   10.8 (median) 
9.6-11.4 (IQR) 
RCT participants 
Hypertensive 
population. 
Nagai et al. 50 Ibaraki prefecture Japan 1993 89,547 Men 60.2 (mean) 
Women 57.8 (mean) 
17.1 (mean) GP 
Exclusion of those 
with history of 
CVD. 
Corsonello et al. 51 InChianti Italy 1998-2000  828 74.4±6.9 (mean±SD)   9 (maximum) GP 
Wu et al 52 Kailuan Study China 2006-2007 95,391 52.0±12.6 (mean±SD)   8 (maximum) GP 
Abbreviations: CVD: cardiovascular disease, DM: diabetes mellitus, GP: general population, HT: hypertension, NA: not available, RCT: 
randomized controlled trial 
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Table 3 
Author [ref] Study name eGFR/ACR 
(GFR 
equation) 
Outcome 
studied 
All-cause 
(ACM) or 
Cardiovascular 
(CVM) 
mortality  
Comparison made + reference 
category 
Adjusted Hazard Ratios in  
exposure categories 
 
(in green results important for 
our purpose) 
Comments 
Manjunath et al. 35 Cardiovascular 
Health Study 
MDRD ACM Reference category:   
90-130 mL/min/1.73m2 
 
60-89 mL/min 1.05 (0.78-1.41) 
15-59 mL/min 1.47 (1.05-2.06) 
 
Go et al. 29 Kaiser 
Permanente Renal 
Registry 
MDRD ACM 
CV events 
Reference category: 
≥ 60 mL/min/1.73m2. 
 
ACM 
45-59 mL/min 1.2 (1.1-1.2) 
30-44 mL/min 1.8 (1.7-1.9) 
15-29 mL/min 3.2 (3.1-3.4) 
< 15 mL/min 5.9 (5.4-6.5) 
CV events 
45-59 mL/min 1.4 (1.4-1.5) 
30-44 mL/min 2.0 (1.9-2.1) 
15-29 mL/min 2.8 (2.6-2.9) 
< 15 mL/min 3.4 (3.1-3.8) 
In a subgroup where chronicity 
was confirmed (repeated serum 
creatinine measurements) 
(n=172,144), eGFR at 45-59 
mL/min was not associated with 
ACM 1.0 (1.0-1.1) 
O’Hare et al 36 Dept. of Veterans 
Affairs 
MDRD ACM Reference category:   
≥ 60 mL/min/1.73m2 
18-44 years 
50-59 mL/min 1.56 (1.30-1.88) 
40-49 mL/min 1.90 (1.35-2.67) 
30-39 mL/min 3.58 (2.54-5.05) 
45-54 years 
50-59 mL/min 1.27 (1.19-1.36) 
40-49 mL/min 1.89 (1.74-2.06) 
30-39 mL/min 2.89 (2.63-3.18) 
55-64 years 
50-59 mL/min 1.18 (1.13-1.23) 
40-49 mL/min 1.75 (1.65-1.85) 
30-39 mL/min 2.43 (2.27-2.59) 
65-74 years 
50-59 mL/min 1.02 (0.99-1.05) 
40-49 mL/min 1.35 (1.32-1.39) 
30-39 mL/min 1.81 (1.75-1.87) 
75-84 years 
50-59 mL/min 1.02 (0.99-1.04) 
40-49 mL/min 1.21 (1.18-1.23) 
30-39 mL/min 1.55 (1.51-1.58) 
85+ years 
In younger age categories 
adjusted HRs were higher and 
statistically significant already 
from 50-59 mL/min.  
In younger people and elderly 
with stable eGFR adjusted HRs 
• were lower in all eGFR 
categories. 
• 50-59 mL/min was not 
associated with ACM 
Findings suggest that mortality 
risk stratification in younger and 
elderly people should not be 
based on the same eGFR cut-off 
points. 
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50-59 mL/min 1.02 (0.97-1.06) 
40-49 mL/min 1.10 (1.05-1.15) 
30-39 mL/min 1.36 (1.29-1.44) 
Maaravi et al. 37 Jerusalem 
Seventy Year 
Olds Longitudinal 
Study 
CG 
MDRD 
Mayo Clinic 
ACM Reference category: 
≥ 60 mL/min/1.73m2. 
Results presented fo MDRD 
< 60 mL/min 1.19 (0.83-1.71) 
 
 
Hallan et al. 38 HUNT II MDRD CVM Reference category:   
≥ 75 mL/min/1.73m2 and 
optimal ACR (ACR below sex 
specific median (<5 and 7 mg/g 
in men and women)) 
 
< 70 years 
Optimal ACR 
60-74 mL/min 1.17 (0.35-3.91) 
45-59 mL/min 0.73 (0.26-2.02) 
< 45 mL/min 1.08 (0.19-6.10) 
High normal ACR 
60-74 mL/min 1.53 (0.55-4.26) 
45-59 mL/min 3.29 (1.02-10.6) 
< 45 mL/min 2.57 (0.88-7.51) 
Micro-albuminuria 
60-74 mL/min 1.92 (0.71-5.16) 
45-59 mL/min 2.22 (0.87-5.70) 
< 45 mL/min 5.94 (2.06-17.2) 
≥ 70 years 
Optimal ACR 
60-74 mL/min 0.79 (0.30-2.10) 
45-59 mL/min 2.48 (0.76-8.13) 
< 45 mL/min 1.49 (0.46-4.86) 
High normal ACR 
60-74 mL/min 1.68 (0.61-4.69) 
45-59 mL/min 1.93 (0.63-5.92) 
< 45 mL/min 4.70 (1.57-14.1) 
Micro-albuminuria 
60-74 mL/min 3.80 (1.33-10.80) 
45-59 mL/min 4.09 (1.52-10.90) 
< 45 mL/min 8.38 (2.83-24.9) 
 
Raymond et al. 56 NA MDRD ACM Reference category: 
≥ 60 mL/min/1.73m2. 
 
20-44 years 
Stage 3a 13.6 (6.2-29.8) 
Stage 3b 12.1 (4.0-36.5) 
Stage 4 17.4 (5.9-51.4) 
Stage 5 26.1 (9.1-74.8) 
45-54 years 
Stage 3a 7.5 (4.4-12.6) 
Stage 3b 13.6 (7.5-24.7) 
Stage 4 4.6 (1.2-17.4) 
Stage 5 28.6 (17.4-47.2) 
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55-64 years 
Stage 3a 3.0 (2.2-4.1) 
Stage 3b 5.9 (3.9-8.9) 
Stage 4 9.3 (6.1-14.2) 
Stage 5 18.2 (13.9-23.9) 
65-74 years 
Stage 3a 1.8 (1.5-2.1) 
Stage 3b 3.2 (2.6-3.9) 
Stage 4 5.2 (4.1-6.5) 
Stage 5 7.6 (5.7-10.1) 
75-84 years 
Stage 3a 1.2 (1.0-1.3) 
Stage 3b 1.9 (1.7-2.1) 
Stage 4 3.3 (2.9-3.8) 
Stage 5 4.4 (3.7-5.3) 
85+ years 
Stage 3a 0.9 (0.8-1.0) 
Stage 3b 1.3 (1.2-1.5) 
Stage 4 1.8 (1.7-2.0) 
Stage 5 2.5 (2.3-2.8) 
Brantsma et al. 39 PREVEND MDRD 
ACR 
CVM and CV 
hospitalization 
combined 
Reference category: no CKD 
 
Stage 1 2.2 (1.5-3.3) 
Stage 2 1.6 (1.3-2.0) 
Stage 3 1.3 (1.0-1.7) 
Stage 3 with UAE < 30 mg/24hr 1.0 
(0.7-1.4) 
Stage 3 with UAE > 30 mg/24 hr 
1.6 (1.1-2.3) 
 
Hwang et al. 40 Elderly Health 
Examination 
Program 
MDRD ACM 
CVM 
Reference category: 
≥ 60 mL/min/1.73m2 
ACM 
45-59 mL/min 1.10 (1.0-1.2) 
30-44 mL/min 1.52 (1.3-1.8) 
15-29 mL/min 2.1 (1.7-2.6) 
< 15 mL/min 2.55 (1.8-3.6) 
CVM 
45-59 mL/min 1.30 (1.0-1.7) 
30-44 mL/min 2.42 (1.7-3.4) 
15-29 mL/min 3.62 (2.3-5.8) 
< 15 mL/min 3.22 (1.3-8.3) 
 
Roderick et al. 41 MRC GP research 
framework 
MDRD 
Dipstick 
proteinuria 
ACM 
CVM in those 
without CVD at 
baseline 
Reference category: 
≥ 60 mL/min/1.73m2 
Proteinuria negative 
ACM after 0-2 years 
Men 
45-59 mL/min 1.13 (0.93-1.37) 
30-44 mL/min 1.69 (1.26-2.28) 
< 30 mL/min 3.87 (2.78-5.38) 
Women 
Short-term (0-2 yr)  eGFR-
related  risk is higher than long 
term (> 2 yr) risk (not shown). 
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45-59 mL/min 1.14 (0.93-1.40) 
30-44 mL/min 1.33 (1.06-1.68) 
< 30 mL/min 2.44 (1.68-3.56) 
CVM after 0-2 years 
Men 
45-59 mL/min 1.67 (1.15-2.43) 
30-44 mL/min 1.60 (0.94-2.73) 
< 30 mL/min 2.89 (1.22-6.84) 
Women 
45-59 mL/min 1.59 (1.01-2.50) 
30-44 mL/min 1.45 (0.93-2.28) 
< 30 mL/min 3.80 (1.87-7.75) 
ACM  
Men 
Proteinuria positive 
> 60 mL/min 1.29 (1.07-1.56) 
45-59 mL/min 1.25 (1.02-1.52) 
30-44 mL/min 1.08 (0.82-1.42) 
< 30 mL/min 0.95 (0.56-1.59) 
Women 
Proteinuria positive 
> 60 mL/min 1.19 (0.96-1.47) 
45-59 mL/min 0.94 (0.77-1.15) 
30-44 mL/min 1.39 (1.10-1.77) 
< 30 mL/min 1.70 (1.15-2.52) 
CVM  
Men 
Proteinuria positive 
> 60 mL/min 1.05 (0.70-1.57) 
45-59 mL/min 1.31 (0.91-1.89) 
30-44 mL/min 0.83 (0.47-1.46) 
< 30 mL/min 0.97 (0.35-2.68) 
Women 
Proteinuria positive 
> 60 mL/min 1.18 (0.80-1.74) 
45-59 mL/min 0.93 (0.65-1.32) 
30-44 mL/min 1.34 (0.88-2.03) 
< 30 mL/min 2.79 (1.40-5.54) 
Van der Velde et al. 42 PREVEND MDRD 
CKD EPI 
CysC 
Combi 
Fatal and non-
fatal CV events 
+ 10 mL/min/1.73M2 increase 
in eGFR. 
Results presented for CKD EPI. 
< 60 years 
0.70 (0.62-0.79) 
≥ 60 years 
1.02 (0.92-1.13) 
The association between eGFR 
and risk of CV events is weaker 
in elderly subjects than in 
younger subjects. 
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Creatinine 
Clearance 
Muntner et al. 43 REGARDS CKD-EPI 
ACR 
ACM Reference category: 
≥ 60 mL/min/1.73m2. 
 
 
 
45-59 years 
45-60 mL/min 2.5 (1.3-4.6) 
< 45 mL/min 3.5 (1.8-6.8) 
60-69 years 
45-60 mL/min 1.7 (1.3-2.3) 
< 45 mL/min 2.2 (1.6-3.0) 
70-79 years 
45-60 mL/min 1.1 (0.9-1.3) 
< 45 mL/min 1.9 (1.5-2.4) 
≥ 80 years 
45-60 mL/min 1.3 (1.0-1.7) 
< 45 mL/min 1.5 (1.1-2.0) 
If ACR is < 10mg/g, the results 
are similar:  
45-59 years 
45-60 mL/min 4.5 (1.8-11.1) 
< 45 mL/min 4.7 (0.7-34.2) 
60-69 years 
45-60 mL/min 1.9 (1.2-3.1) 
< 45 mL/min 2.5 (1.0-6.1) 
70-79 years 
45-60 mL/min 1.1 (0.8-1.6) 
< 45 mL/min 2.1 (1.2-3.6) 
≥ 80 years 
45-60 mL/min 1.4 (0.9-2.2) 
< 45 mL/min 1.6 (0.9-2.8) 
Stengel et al.44 Three City CKD-EPI 
MDRD 
ACM 
CVM 
Reference category: 
≥ 75-89 mL/min/1.73m2 
Results presented for CKD-EPI. 
ACM 
60-74 mL/min 0.9 (0.8-1.1) 
45-59 mL/min 1.1 (0.9-1.3) 
30-44 mL/min 2.0 (1.5-2.7) 
< 30 mL/min 3.3 (2.0-5.5) 
CVM 
60-74 mL/min 0.9 (0.6-1.3) 
45-59 mL/min 1.6 (1.1-2.3) 
30-44 mL/min 3.1 (1.8-5.0) 
< 30 mL/min 4.3 (1.8-10.2) 
 
Van Pottelbergh et al. 
45 
BELFRAIL MDRD 
CKD-EPI 
Creat 
CKD-EPI 
Cyst 
CKD-EPI 
Creatcyst 
BIS 
ACM and RRT 
combined 
Reference category: 
60-90 mL/min/1.73m2. 
Results presented for CKD-EPI 
SCr. 
 
45-60 mL/min 1.65 (1.05-2.61) 
30-45 mL/min 1.72 (1.03-2.88) 
<30 mL/min 5.04 (2.95-8.60) 
 
 
Oh et al. 46 KLoSHA CKD-EPI 
ACR 
ACM Reference category: 
≥ 90 mL/min/1.73m2 
Proteinuria negative 
60-89 mL/min 1.37 (0.75-2.52) 
45-59 mL/min 1.65 (0.84-3.25) 
< 45 mL/min 2.36 (1.17-4.75) 
 
If proteinuria (strips) 
Trace 1.24 (0.78-1.96) 
≥ 1+  1.73 (1.13-2.63) 
Minutolo et al. 47 Health 
Search/Cegedim 
Strategic Data 
Longitudinal 
Patient Database 
MDRD ACM 
 
Reference category: 
≥ 60 mL/min/1.73m2. 
 
ACM 
Stage 3a 1.11 (0.99-1.23) 
Stage 3b 1.66 (1.49-1.86) 
Stage 4 2.75 (2.41-3.13) 
Stage 5 2.54 (2.01-3.22) 
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Malmgren et al.48 NA CKD-EPI 
MDRD 
Revised 
Lund-Malmö 
BIS-1 
Cockroft-
Gault 
ACM Reference category: 
≥ 60 mL/min/1.73m2. 
Results presented for CKD-EPI. 
75-80 years 
45-60 mL/min 1.1 (0.6-2.0) 
0-45 mL/min 4.5 (2.2-9.2) 
75-85 years 
45-60 mL/min 1.4 (1.0-1.9) 
0-45 mL/min 3.5 (2.1-5.8) 
80-85 years 
45-60 mL/min 1.7 (1.1-2.6) 
0-45 mL/min 2.6 (1.4-5.0) 
 
Chowdhury et al. 49 ANBP2 MDRD 
CKD-EPI 
ACM 
CVM 
Reference category: 
≥ 60 mL/min/1.73m2. 
Results presented for CKD-EPI. 
 
ACM 
45-59 mL/min 1.13 (1.01-1.27) 
30-44 mL/min 1.65 (1.37-1.99) 
< 30 mL/min 5.16 (3.17-8.42) 
CVM 
45-59 mL/min 1.05 (0.89-1.23) 
30-44 mL/min 1.64 (1.27-2.13) 
< 30 mL/min 5.60 (2.32-13.51) 
 
Nagai et al. 50 Ibaraki prefecture MDRD ACM 
CVM 
Reference category: 
≥ 60 mL/min/1.73m2. 
 
ACM 
Men 
40-69 years 
45-49 mL/min 1.33 (1.06-1.67) 
30-44 mL/min 1.53 (1.20-1.96) 
70-80 years 
45-49 mL/min 1.02 (0.82-1.25) 
30-44 mL/min 1.63 (1.33-2.00) 
Women 
40-69 years 
45-49 mL/min 1.50 (1.27-1.78) 
30-44 mL/min 2.21 (1.81-2.71) 
70-80 years 
45-49 mL/min 1.19 (1.02-1.38) 
30-44 mL/min 1.53 (1.31-1.79) 
CVM 
Men 
40-69 years 
45-49 mL/min 1.82 (1.23-2.69) 
30-44 mL/min 1.65 (1.04-2.62) 
70-80 years 
45-49 mL/min 1.03 (0.72-1.48) 
30-44 mL/min 1.37 (0.93-2.02) 
Women 
40-69 years 
45-49 mL/min 1.34 (0.98-1.82) 
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30-44 mL/min 2.24 (1.58-3.17) 
70-80 years 
45-49 mL/min 1.43 (1.14-1.79) 
30-44 mL/min 1.57 (1.23-2.00) 
Corsonello et al. 51 InChianti CKD-EPI SCr 
BIS1 SCr 
FAS 
CKD EPI 
SCr-CysC 
Bis2 SCr-
CysC 
ACM Reference category:   
≥ 90 mL/min/1.73m2 
Results presented for CKD-EPI 
SCr 
 
60-89.9 mL/min 1.63 (0.84-3.17) 
45-59.9 mL/min 2.50 (1.21-5.15) 
30-44.9 mL/min 5.44 (1.10-27.7) 
<30 mL/min 7.42 (1.79-30.6) 
 
 
Wu et al. 52 Kailuan Study CKD-EPI 
ACR 
ACM Reference category:   
≥ 90 mL/min/1.73m2 
All 
60-89 mL/min 1.01 (0.93-1.09) 
45-59 mL/min 1.11 (0.99-1.24) 
<45 mL/min 1.51 (1.30-1.74) 
Men 
60-89 mL/min 1.01 (0.94-1.10) 
45-59 mL/min 1.11 (0.99-1.23) 
<45 mL/min 1.35 (1.17-1.57) 
Women 
60-89 mL/min 1.65 (1.16-2.34) 
45-59 mL/min 1.92 (1.25-2.96) 
<45 mL/min 4.11 (2.50-6.76) 
 
Abbreviations: ACR: albumin-to-creatinine ratio, BIS: Berlin Intitiative Study, CKD EPI: Chronic Kidney Disease Epidemiology Collaboration 
equation, SCr: serum creatinine, CV: cardiovascular, CVD: cardiovascular disease, CysC; cystatin C, eGFR: estimated Glomerular Filtration 
Rate, FAS: Full Age Spectrum, GP: general population, MDRD: Modified Diet in Renal Disease Study equation, NA: not available 
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Figure 1. 
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Figure 2. 
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Figure 3. 
 
 
